Clinical trials: Post-tuberculosis Lung Disease
Post Tuberculosis
Mechanisms, Biomarkers and Pulmonary Rehabilitation in Post-TB Lung Disease
Tuberculosis (TB) affects millions of people worldwide, and many individuals continue to experience long-term health problems even after completing TB treatment.
- Trial name
- AFTER-TB (NCT07731009)
- Testing
- Pulmonary rehabilitation
- Volunteers
- 760 people
- Sponsor
- Jose Antonio Dominguez Benitez
Prevention of TB Recurrence
Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence
This is a Phase II/III trial with two groups of adults successfully cured of category 1 pulmonary TB receiving either VPM1002 or placebo.
- Trial name
- NCT03152903
- Testing
- VPM1002 (Recombinant BCG Vaccine)
- Where
- 10 sites in Bangladesh, India
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Post Tuberculosis, Lung Disease
TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease
Post-Tuberculosis Lung Disease (PTLD) is defined as chronic respiratory impairment due to previous pulmonary TB. Children recovering from pulmonary TB undergo ongoing respiratory health challenges, including more frequent…
- Conditions
- Post Tuberculosis, Lung Disease, Functional Capacity, Spirometry
- Trial name
- NCT07451899
- Where
- Indonesia
- Volunteers
- 23 people
- Sponsor
- Universitas Padjadjaran
Pulmonary Tuberculosis
Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion
The purpose of this study is to evaluate the safety and immunogenicity of ID93 + GLA-SE vaccine when administered to adult pulmonary Tuberculosis (TB) patients, following successful completion of TB treatment with confirmed…
- Trial name
- NCT02465216
- Testing
- ID93 + GLA-SE
- Where
- 3 sites in South Africa
- Volunteers
- 60 people
- Sponsor
- Access to Advanced Health Institute (AAHI)
Pulmonary Tuberculosis
Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)
The purpose of this study is to assess the mycobactericidal activity of the moxifloxacin plus PA-824 plus pyrazinamide regimen after 8 weeks of treatment.
- Trial name
- NCT01498419
- Testing
- Moxifloxacin (M), Pretomid (Pa), Pyrazinamide (Z)
- Where
- 8 sites in South Africa, Tanzania
- Volunteers
- 207 people
- Sponsor
- Global Alliance for TB Drug Development
Bronchiectasis Post-Tuberculosis Lung Disease
Respiratory Muscle Stretching for Improving Chest Expansion and Dyspnea in Post-Tuberculosis Bronchiectasis
This study intends to examine the effectiveness of adding RMS to a traditional program of pulmonary rehabilitation regarding chest expansion, dyspnea, and cough symptoms in bronchiectasis post-tuberculosis patients.
- Trial name
- NCT06597409
- Testing
- Standard PR, Standard PR plus Respiratory Muscle Stretching (RMS)
- Where
- Indonesia
- Volunteers
- 48 people
- Sponsor
- Universitas Padjadjaran
TB - Tuberculosis, TB
Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)
Individual-level, unblinded randomized controlled trial of an 8-week (short arm) or 24-week (extended arm) pulmonary rehabilitation program, relative to standard of care, to prevent post-tuberculosis respiratory morbidity.
- Conditions
- TB - Tuberculosis, TB, TB Infection
- Trial name
- TB Pure (NCT07164742)
- Testing
- 8 week (short arm) Intervention - pulmonary rehabilitation, 24 week (long arm) Intervention - pulmonary rehabilitation
- Where
- 2 sites in India
- Volunteers
- 690 people
- Sponsor
- Johns Hopkins University
Tuberculosis, Pulmonary
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
The purpose of this study is to investigate the effectiveness and safety of the regimen including high dose rifampicin for individualized duration (3 months after Culture Conversion) for the treatment of drug-sensitive pulmonary…
- Trial name
- Hi-DoRi-3 (NCT04485156)
- Testing
- High-dose rifampicin, Isoniazid, Pyrazinamide
- Where
- South Korea
- Volunteers
- 926 people
- Sponsor
- Seoul National University Hospital
Tuberculosis
Improving the Outcomes of Children With Tuberculosis Through Innovative Diagnostics and Treatment Monitoring
This study aims at identifying and evaluating novel diagnostic methods for children evaluated for respiratory tuberculosis. The investigators will use alternative samples like stool, urine, and masks to diagnose children with…
- Trial name
- RoGer Pedi (NCT06815588)
- Where
- Romania
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Research Center Borstel
Pulmonary Tuberculosis, Extra Pulmonary Tuberculosis
Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance
Brazil ranks 17th among the 22 countries responsible for 80% of tuberculosis (TB) cases in the world. In 2010, the number of new cases of tuberculosis in Brazil was 71,930 and in 4972 RS.
- Trial name
- NCT02558842
- Testing
- Education Strategy
- Where
- Brazil
- Volunteers
- 160 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
COVID-19, Tuberculosis
Tuberculosis as a Risk Factor for a Worse Outcome Post-Sars-CoV-2 Infection
This study has two main objectives. First, the clinical characteristics and outcomes of hospitalized patients with symptomatic Covid-19 disease will be compared between persons with a history of past or current TB infection or…
- Conditions
- COVID-19, Tuberculosis, Post-acute COVID-19 Syndrome
- Trial name
- Co-TB (NCT05643781)
- Where
- South Africa
- Volunteers
- 157 people
- Sponsor
- The Aurum Institute NPC
Tuberculosis, Pulmonary
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in…
- Trial name
- StatinTB (NCT04147286)
- Testing
- Atorvastatin 40mg
- Where
- South Africa
- Volunteers
- 220 people
- Sponsor
- University of Cape Town
Tuberculosis in Children, Chronic Lung Disease
Paediatric Post-TB Pulmonary Rehab Study
The goal of this clinical trial is to learn if a home-based pulmonary rehabilitation program is feasible and acceptable for children ages 6-15 who have recently completed treatment for pulmonary tuberculosis.
- Conditions
- Tuberculosis in Children, Chronic Lung Disease, Post Tuberculosis
- Trial name
- PPT Rehab (NCT07097961)
- Testing
- Pulmonary Rehabilitation
- Where
- Uganda
- Volunteers
- 40 people
- Sponsor
- University of Iowa
Hepatitis, Tuberculosis, Pulmonary
Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment
Despite the availability of effective anti-tuberculosis agents that exist to treat this illness, hepatotoxicity during first-line drugs anti-tuberculosis medications (ATT) such as isoniazid (INH), rifampin (RIF), and pyrazinamide…
- Trial name
- NCT01395654
- Testing
- isoniazid, rifampin, pyrazinamide
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Pulmonary Tuberculoses, Pulmonary Function; Newborn, Abnormal
Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.
Some of pulmonary tuberculous patients who completed their medication course experience lung function impairment
- Trial name
- NCT05097638
- Testing
- spirometry
- Where
- Egypt
- Volunteers
- 210 people
- Sponsor
- Assiut University
Post-tuberculosis Lung Disease, Tuberculosis (TB)
Pulmonary Rehabilitation Program in Patients With Post-Tuberculosis Lung Disease
Post-tuberculosis lung disease (PTLD) refers to persistent respiratory symptoms, functional limitation, and/or structural or physiological abnormalities after completion of anti-tuberculosis treatment.
- Trial name
- NCT07709507
- Testing
- Individualized Pulmonary Rehabilitation Program, Standard Post-Tuberculosis Care
- Volunteers
- 80 people
- Sponsor
- Filantropia Hospital
Tuberculosis (TB)
A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease
The goal of this clinical trial is to evaluate if N-acetylcysteine (NAC) works to prevent post-tuberculosis lung disease (PTLD) in patients with severe pulmonary impairment. It also aims to assess the safety of NAC.
- Trial name
- NAC-PTLD (NCT06909799)
- Testing
- N-Acetyl Cysteine (NAC), Standard TB treatment
- Where
- The Gambia
- Volunteers
- 242 people
- Sponsor
- The Aurum Institute NPC
Tuberculosis, Pulmonary, Household Contacts
Airborne Preventive Measures to Reduce New TB Infections in Household Contacts
Tuberculosis (TB) is currently one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS).
- Conditions
- Tuberculosis, Pulmonary, Household Contacts, Tuberculosis
- Trial name
- TBMask (NCT04938596)
- Testing
- Respiratory bundle
- Where
- Chile
- Volunteers
- 432 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Tuberculosis, Post-Tuberculous Pleural Fibrosis
Endurance Training in Patients With Post-TB Lung Disease
To determine the effects of endurance training on functional capacity and QOL(Quality of life) in patients with post-TB (tuberculosis) lung disease. Post-tuberculosis lung disease is a major health concern nowadays.
- Conditions
- Tuberculosis, Post-Tuberculous Pleural Fibrosis, Post-Tuberculous Bronchiectasis
- Trial name
- NCT06047795
- Testing
- Experimental, Control
- Where
- Pakistan
- Volunteers
- 36 people
- Sponsor
- Riphah International University
Tuberculosis
Evaluation of Tuberculosis Treatment Outcomes
Tuberculosis (TB) is an infectious disease caused by Mycobacterium species grouped in the Mycobacterium tuberculosis complex. TB remains a major global health problem, despite the fact that there are drugs that can eradicate the…
- Trial name
- CLIO-TB (NCT06942975)
- Testing
- Patients with turberculosis
- Where
- Italy
- Volunteers
- 111 people
- Sponsor
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria